Report: Former HHS secretary Mike Leavitt to lead GOP hopeful’s health policy efforts
WASHINGTON — Former secretary for the Department of Health and Human Services Mike Leavitt will lead presidential hopeful Mitt Romney’s transition planning should Romney win the fall elections, according to a report published Wednesday by National Journal Daily.
Leavitt helped author the prescription coverage under Medicare Part D during his tenure at HHS.
According to the report, Leavitt, a former Utah governor, will also be in charge of implementing any health reforms under Romney. The report identified Tevi Troy, Leavitt‚ former deputy at HHS, and Thomas Barker, now a partner at Foley Hoag, who also worked for Leavitt at HHS as prominent members on Romney’s health advisory team, along with Scott Gottlieb, now with the American Enterprise Institute, who served as a senior adviser at the Centers for Medicare and Medicaid Services during the Bush years and later became a deputy commissioner at the Food and Drug Administration.
For the full report, click here.
Hospira buys Indian manufacturing, R&D center
LAKE FOREST, Ill. — Generic drug maker Hospira has acquired a manufacturing and research and development center from an Indian drug maker for $200 million, Hospira said Wednesday.
Hospira said it bought the Food and Drug Administration-approved active pharmaceutical ingredient factory and R&D facility in Aurangabad, India, from Orchid Chemicals and Pharmaceuticals, saying it would reduce Hospira’s costs, support its supplying of antibiotics and pave the way for future API development.
"Our decision to acquire Orchid’s world-class API facility demonstrates Hospira’s continued dedication to the antibiotics space, enchanting cost-competitiveness and ensuring continuity of supply," Hospira India managing director C. Bhaktavatsala Rao said. "This is a top-of-the-line API manufacturing facility that has been recognized by industry leaders for its high standards. We look forward to welcoming our new colleagues from Orchid and leveraging their expertise to continue to bring high-quality, lower-cost products to patients around the world."
Lilly promotes Michael Harrington to SVP, general counsel
INDIANAPOLIS — Eli Lilly announced that Michael Harrington will be promoted to SVP and general counsel, effective Jan. 1, 2013.
Harrington — who currently serves as VP and deputy general counsel for the drug maker and is responsible for the legal function across Lilly’s five business units — will replace Robert Armitage, who will retire at the end of the year. In his new role, Harrington will report to Lilly chairman, president and CEO John Lechleiter and will serve on the company’s executive committee.
"We are very fortunate to have Mike Harrington to take Bob’s place. Mike is well-prepared for his new assignment," Lechleiter said."He has been instrumental in handling many of the key legal challenges we have faced in the last few years. His extensive global experience, deep knowledge of the business, and his passion for Lilly’s mission will serve our company well."